In mice with rheumatoid arthritis, a nanoparticle that delivers a tolerance-promoting drug and a B cell inhibitor together is linked to higher levels of regulatory T cells and lower levels of antibody-producing cells.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether this nanoparticle design consistently induces both Treg expansion and plasma cell reduction across multiple independent studies in autoimmune mouse models.
A systematic review and meta-analysis pooling Treg frequency and plasma cell counts from all peer-reviewed studies using this nanoparticle platform in K/BxN or CIA mouse models, with standardized flow cytometry protocols and outcome definitions.
Whether the nanoparticle directly causes both Treg increase and plasma cell decrease in a controlled setting.
A double-blind, randomized controlled trial in 60 K/BxN mice, randomized to nanoparticle, placebo nanoparticle, or saline, with Treg (CD4+FoxP3+) and plasma cell (CD138+IgG+) frequencies quantified via flow cytometry in spleen and lymph nodes at day 28 as primary endpoints.
Whether nanoparticle exposure predicts the magnitude of Treg increase and plasma cell decrease over time in a defined mouse cohort.
A prospective cohort study of 100 K/BxN mice receiving the nanoparticle at disease onset, tracking Treg and plasma cell frequencies weekly for 8 weeks, adjusting for baseline disease severity and genetic variability.
Whether nanoparticle-treated mice with high Treg/low plasma cell profiles differ from untreated mice with low Treg/high plasma cell profiles.
A case-control study comparing 30 mice with >20% Treg increase and >50% plasma cell reduction (cases) to 30 with minimal changes (controls), retrospectively assessing nanoparticle exposure and immune history.
Whether nanoparticle-treated mice at a single timepoint show higher Treg and lower plasma cell frequencies than untreated mice.
A cross-sectional comparison of Treg and plasma cell frequencies in 40 nanoparticle-treated and 40 untreated K/BxN mice at day 30 post-treatment, with no longitudinal tracking.